Anti White Powder Toremifene Citrate Anabolic Hormones Anti Estrogen Steroids
Toremifene Citrate/Fareston Specification:
Toremifene Citrate Name | Toremifene citrate |
Toremifene Citrate Synonyms | FC 1157A; Fareston; NK 622; NSC 613680 |
Toremifene Citrate CAS | 89778-27-8 |
Toremifene Citrate Assay | 99% min |
Toremifene Citrate PSA | 144.60000 |
Toremifene Citrate LogP | 4.96650 |
Toremifene Citrate Appearance & Physical State | White or almost white powder |
Toremifene Citrate Density | 1.045g/cm3 |
Toremifene Citrate Melting Point | 158-164ºC |
Toremifene Citrate Boiling Point | 535.1ºC at 760 mmHg |
Toremifene Citrate Flash Point | 277.4ºC |
Toremifene Citrate Refractive Index | 1.416-1.418 |
Toremifene Citrate Storage Condition | -20ºC Freezer |
Toremifene Citrate Half Life | 5 days |
Toremifene Citrate Detection Time | Unknown |
Toremifene Citrate Anabolic Rating | N/A |
Toremifene Citrate Androgenic Rating | N/A |
Toremifene Citrate/Fareston Description:
Toremifene (also known under its brand and trade name of Fareston) is a member of a category, family, and class of drugs that are known as SERMs (Selective Estrogen Receptor Modulators). SERMs fall under an even broader category of drugs that are known as anti-estrogens, and the cousin family of SERMs (that also fall under anti-estrogens) are aromatase inhibitors, commonly abbreviated as AIs.
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene. SERMs include compounds such as Toremifene, Nolvadex(Tamoxifen), and Clomid (Clomiphene Citrate). Aromatase inhibitors (AIs) include compounds such as Arimidex (Anastrozole), Aromasin (Exemestane), and Letrozole (Femara).
Toremifene Citrate/Fareston Benefits:
- It is clinically proven. In a number of important measurements of a drug’s effectiveness in treating metastatic ER+ breast cancer in postmenopausal women, Fareston worked just as well as tamoxifen1-4
- May provide the continued benefits of endocrine therapy. Fareston may offer you the continued benefits of endocrine therapy if you cannot tolerate or are otherwise unable to take other endocrine therapies1-6
- Fareston may be an effective alternative for patients who have stopped taking other endocrine therapies because of joint pain1-4,6
- Is available and accessible. Fareston is widely available on commercial and Medicare Part D formularies and is covered by most commercial and Medicare insurance plans.